Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Aesica Appoints New Product Release Manager

Published: Wednesday, August 20, 2014
Last Updated: Wednesday, August 20, 2014
Bookmark and Share
Company announces appointment of Adam Burgess.

Aesica has announced the appointment of Adam Burgess to the position of Product Release Manager. Adam’s wide ranging role includes managing the Qualified Persons team; directing and controlling QP activities in line with operational requirements, the role also involves the development of quality systems, product release, facilitating process improvements and acting as a Qualified Person.

Based at Queenborough, UK Adam has responsibility for pharmaceutical quality assurance across the Kent based site. A key function is to ensure on time release of products. He will work closely with production personnel at the site, with the specific goal of ensuring that operational departments build quality into their processes and organizational structures. Adam reports directly to Christine Ernst, the Site Head of Quality at Aesica, Queenborough, UK.

Previously, he held the position of Manager, Defective Medicines Report Centre and Import Notification at the MHRA and was an active Qualified Person at Martindale Pharma. Prior to that, he worked as a QA Manager in Preclinical Quality Assurance at GlaxoSmithKline. His expertise reaches across both commercial and clinical trial products including steriles, non-sterile tablets, capsules and liquids.

Adam brings Quality Assurance experience in laboratory, packaging and manufacturing area settings. He has strong skills in the risk assessment of pharmaceutical products and has authored position papers focused both on product quality and patient safety implications of unplanned events.

Remarking on his new position, Adam Burges said: “I am delighted to be appointed to this role at Aesica. It affords me the opportunity to return to pharmaceutical manufacturing and packaging, bringing the experience that I have gained at the UK regulator. This experience will help me to further enhance and drive quality culture initiatives across the company - in particular at Queenborough. I am looking forward to leading the Product Release team to ensure that all staff fully understand customer needs, consistently deliver results, whilst maintaining the high quality levels demanded and expected.”

Commenting on Adam Burgess’s appointment, Indira Walker, Corporate Quality Director at Aesica remarked: “We are delighted that Adam has joined our Quality Assurance team. He brings strong Quality Assurance expertise and we are especially impressed by his combined experience of working both for prominent pharmaceutical companies and the MHRA regulatory authority.”

She continued “We look forward to Adam contributing significantly to making further inroads into driving up QA standards so that we deliver the most consistent and best-in-class quality of service within the industry.”


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Aesica Secures Continuing FDA Approval of its Bulk Manufacture and Packaging Sites
FDA inspection results means Aesica will continue to grow its manufacturing and packaging services for pharmaceutical products for the US market.
Tuesday, February 03, 2015
Aesica Appoints VP, Business Development and Business Development Director
Appointment of Detlef Behrens and Sven Wrabletz for finished dose to drive service in Europe and achieve further growth.
Friday, October 31, 2014
Aesica Zwickau Marks 20th Anniversary
Continued growth and expansion of Company’s encapsulation services business.
Saturday, July 19, 2014
Aesica Recruits New Business Development Manager
Appointment of Nadine K. Reuter to aid sales drive across German, Austrian and Swiss Markets.
Thursday, July 03, 2014
Aesica Collaborates with QAD to Meet CFDA’s Shortened Serialization Deadline
The new system was implemented within three months.
Saturday, June 28, 2014
Aesica Successfully Introduces Serialization Services at Italian Site
Initiates commercial production of two product lines for the Chinese market.
Thursday, April 17, 2014
Aesica Led Consortium Wins Technology Strategy Board Grant
Funding secured for the consortium’s project to investigate an industrial biotechnology process to enable improved manufacture of an API.
Tuesday, April 08, 2014
Aesica Completes the Validation of its High Capacity Manufacturing Facility
$45m (USD) has been invested at its Queenborough, UK site.
Saturday, March 15, 2014
Aesica Appoints Ian Muir to Commercial Managing Director Position
Key functions centre on the Group’s commercial business and product pipeline development across API, formulation development and formulated products.
Tuesday, February 04, 2014
Aesica Awarded NEPIC Industry Award
Corporate HR Manager wins NEPIC 2014 Young Achiever Accolade within the Pharmaceutical category.
Thursday, January 30, 2014
Aesica Appoints New Site Manufacturing Manager at Cramlington Facility
Tasked with optimizing performance schedules, including 4 new products for 2014.
Tuesday, November 26, 2013
Aesica Recruits New East Coast Business Development Manager
Appointment of Baali Muganga to spearhead growth in contract manufacturing market share across the US region.
Tuesday, October 29, 2013
Aesica Target Development Services at Growing Inhalation Market
CDMO’s Nottingham site a hot bed of innovation with unique spray drying, powder filling and dry powder inhaler technology.
Wednesday, October 16, 2013
Aesica Unveils a New High Capacity Manufacturing Facility
New facility specifically built to produce a solid dose medication for treating Type 2 diabetes in adults.
Thursday, September 19, 2013
Aesica Appoints Bhavesh Kotecha to Newly Created Position of CSD
Role to oversee a Group wide services of IT, M&A process planning, health and safety, and internal audit system.
Thursday, August 29, 2013
Scientific News
Experimental MERS Vaccine Shows Promise in Animal Studies
A two-step regimen of experimental vaccines against Middle East respiratory syndrome (MERS) prompted immune responses in mice and rhesus macaques, report National Institutes of Health scientists who designed the vaccines.
Young South African Women can Adhere to Daily PrEP Regimen as HIV Prevention
NIH-funded study finds men in Bangkok, Harlem also successful in taking daily dose.
Researchers Find Key Player in Diabetic Kidney Disease Through Power of Metabolomics
Discovery could lead to new and better diagnostic marker for chronic kidney disease.
Immunotherapy Shows Promise for Myeloma
A strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
Santhera Announces First Patient Dosing with Omigapil in CMD
Company announces full patient recruitment of CALLISTO study.
Study Shows Promise of Precision Medicine for Most Common Type of Lymphoma
The study appeared online July 20, 2015, in Nature Medicine.
HIV Control Through Treatment Durably Prevents Heterosexual Transmission of Virus
NIH-funded trial proves suppressive antiretroviral therapy for HIV-infected people effective in protecting uninfected partners.
Adaptimmune's Novel Cancer Therapeutics Show Positive Clinical Trial Results
The company has announced that positive data from its Phase I/II study of its affinity enhanced T-cell receptor (TCR) therapeutic targeting the NY-ESO-1 cancer antigen in patients with multiple myeloma has been published.
Early Antiretroviral Therapy Prevents Non-AIDS Outcomes in HIV-infected People
NIH-supported findings illustrate manifold benefit of therapy.
Adaptimmune’s NY-ESO-1 TCR-engineered T-Cells Demonstrate Durable Persistence
Study has been published in Nature Medicine.
Scroll Up
Scroll Down
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!